Effects of a high fructose diet on gut health and metabolism

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates how a high fructose diet affects metabolic health by altering the gut microbiome. It involves a controlled cross-over dietary intervention where 30 participants will consume either a fructose or glucose diet for 12 days, separated by a 10-day washout period. The participants will be selected based on their fructose malabsorption status, determined through a hydrogen breath test. The goal is to understand the mechanisms linking dietary fructose to metabolic outcomes, particularly in relation to conditions like Type 2 Diabetes and obesity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must be determined to be a fructose malabsorber (screening visit) via hydrogen breath test.

Exclusion Criteria:

* Use of probiotic/prebiotic/synbiotic supplements
* Consumption of \> 1 sugar sweetened beverage per day
* Antibiotics within 3 months prior to enrollment or during intervention
* Vegetarian, vegan or other restrictive dietary habits
* Food allergy
* Alcohol consumption in excess of 2 drink per day

The following additional factors will be exclusion criteria:

* Physician diagnosis of a major medical illness (including type 1 or type 2 diabetes) or eating disorder
* Physical, mental, or cognitive handicaps that prevent participation
* Chronic use of any medication that may affect body weight or composition, insulin resistance, or lipid profiles;
* Current smoking (more than 1 cigarette in the past week) or use of other recreational drugs; e) restrictive dietary habits;
* food allergy;
* excess alcohol consumption;
* recent use of pro-, pre- or Synbiotics of receipt of antibiotics within 3 months prior to enrollment or during the intervention;
* consumption of greater than 1 sugar sweetened beverage per day prior to enrollment

Where it's running

• Mount Sinai Morningside
  New York, New York, United States Recruiting

Study contacts

• Principal investigator: Ryan Walker — Icahn School of Medicine at Mount Sinai
• Study coordinator: Ryan Walker, PhD
• Email: ryan.walker@mssm.edu
• Phone: 212-824-7088

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Screening patients at risk for liver disease in Europe

  This study is trying to find out if screening high-risk patients in Europe for liver disease using simple tests can help doctors identify and better understand conditions like metabolic dysfunction-associated steatotic liver disease.

  Recruiting at 6 sites Julius Clinical · Brussels, Vlaams-brabant and 12 other locations · NCT05651724

• Switching to Zenagamtide From Tirzepatide in Adults With Overweight or Obesity With or Without Type 2 Diabetes

  This study tests whether adults who are overweight or have obesity (with or without type 2 diabetes) can switch from tirzepatide to a new treatment called zenagamtide to find a tolerable dose.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07868354

• Switching to Zenagamtide from Semaglutide in adults with overweight or obesity, with or without type 2 diabetes

  This study tests whether adults who are already taking semaglutide can successfully switch to zenagamtide at different doses to see which dose works best.

  Recruiting at 2 sites Phase 1 Novo Nordisk A/S · Glendale, California and 1 other locations · NCT07855133

• Using Multimodal Ultrasound to Check Muscle Mass in Metabolic Disease Patients

  This study tests whether a multimodal ultrasound approach can accurately measure muscle mass in people with metabolic syndrome, obesity, sarcopenia, or type 2 diabetes.

  Recruiting Zhangzhou Municipal Hospital · Zhangzhou, Fujian · NCT07836088

• GUB-UCN2 in healthy, obese, and T2D adults: a first-in-human safety and pharmacology study

  This study tests GUB-UCN2 to see if it is safe and tolerable and how it behaves in the body in healthy adults, people with obesity, and people with obesity with or without type 2 diabetes.

  Recruiting Phase 1/2 Gubra A/S · Neuss · NCT07702890

• Two doses of CagriSema plus one dose of Semaglutide for weight loss in obesity with or without type 2 diabetes

  This study tests whether two doses of CagriSema, plus a dose of Semaglutide, help adults with obesity (with or without type 2 diabetes) lose weight.

  Recruiting Phase 3 Novo Nordisk A/S · Birmingham, Alabama and 302 other locations · NCT07564414

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.